237 related articles for article (PubMed ID: 17315159)
1. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
Aziz Z; Iqbal J; Akram M; Saeed S
Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
3. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
4. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib].
Wang GR; Zhao YZ; Qian LS; Zou DH; Li R; Mi YC; Wang XX; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):18-22. PubMed ID: 18512310
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
7. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
8. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
9. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
10. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
11. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
13. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cortes JE; Talpaz M; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Rios MB; Shan J; Kantarjian HM
Cancer; 2006 Mar; 106(6):1306-15. PubMed ID: 16463391
[TBL] [Abstract][Full Text] [Related]
14. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
[TBL] [Abstract][Full Text] [Related]
15. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
16. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
17. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]